Equities research analysts at HSBC initiated coverage on shares of Haleon (LON:HLN – Get Free Report) in a report released on Thursday, LSE.Co.UK reports. The firm set a “buy” rating on the stock.
Separately, Barclays cut their price objective on Haleon from GBX 390 ($4.85) to GBX 383 ($4.77) and set an “overweight” rating on the stock in a research report on Tuesday, April 9th.
Check Out Our Latest Report on Haleon
Haleon Trading Up 0.6 %
Insiders Place Their Bets
In related news, insider Tobias Hestler sold 23,564 shares of Haleon stock in a transaction on Friday, March 1st. The stock was sold at an average price of GBX 329 ($4.10), for a total transaction of £77,525.56 ($96,508.85). Insiders own 22.53% of the company’s stock.
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Recommended Stories
- Five stocks we like better than Haleon
- Investing In Automotive Stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is a Stock Market Index and How Do You Use Them?
- 3 Steel Stocks Could Soar on New China Tariffs
- 3 Fintech Stocks With Good 2021 Prospects
- Bear Market Funds to Watch This Year
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.